AR056082A1 - Formas cristalinas de clorhidrato de irinotecano (monoclorhidrato de 7-etil-10-[4-(1-piperidin)-1-piperidin]carboniloxicamptotecina trihidratado) y metodos de preparacion de las mismas - Google Patents

Formas cristalinas de clorhidrato de irinotecano (monoclorhidrato de 7-etil-10-[4-(1-piperidin)-1-piperidin]carboniloxicamptotecina trihidratado) y metodos de preparacion de las mismas

Info

Publication number
AR056082A1
AR056082A1 ARP060104123A ARP060104123A AR056082A1 AR 056082 A1 AR056082 A1 AR 056082A1 AR P060104123 A ARP060104123 A AR P060104123A AR P060104123 A ARP060104123 A AR P060104123A AR 056082 A1 AR056082 A1 AR 056082A1
Authority
AR
Argentina
Prior art keywords
crystalline form
irinotecan hydrochloride
hydrochloric acid
piperidin
ethanol
Prior art date
Application number
ARP060104123A
Other languages
English (en)
Spanish (es)
Inventor
Shu-Ping Chen
Piin-Jye Harn
Original Assignee
Scinopharm Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Singapore Pte Ltd filed Critical Scinopharm Singapore Pte Ltd
Publication of AR056082A1 publication Critical patent/AR056082A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP060104123A 2005-09-20 2006-09-21 Formas cristalinas de clorhidrato de irinotecano (monoclorhidrato de 7-etil-10-[4-(1-piperidin)-1-piperidin]carboniloxicamptotecina trihidratado) y metodos de preparacion de las mismas AR056082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71882705P 2005-09-20 2005-09-20

Publications (1)

Publication Number Publication Date
AR056082A1 true AR056082A1 (es) 2007-09-19

Family

ID=37889452

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104123A AR056082A1 (es) 2005-09-20 2006-09-21 Formas cristalinas de clorhidrato de irinotecano (monoclorhidrato de 7-etil-10-[4-(1-piperidin)-1-piperidin]carboniloxicamptotecina trihidratado) y metodos de preparacion de las mismas

Country Status (14)

Country Link
US (1) US7435818B2 (enExample)
EP (2) EP2082741A1 (enExample)
JP (1) JP5119153B2 (enExample)
KR (1) KR101150504B1 (enExample)
CN (1) CN101277694B (enExample)
AR (1) AR056082A1 (enExample)
AT (1) ATE460162T1 (enExample)
AU (1) AU2006292328B2 (enExample)
BR (1) BRPI0616308A2 (enExample)
CA (1) CA2623117C (enExample)
DE (1) DE602006012871D1 (enExample)
ES (1) ES2343204T3 (enExample)
NZ (1) NZ566807A (enExample)
WO (1) WO2007035709A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101318964B (zh) * 2007-06-07 2010-12-15 上海迪赛诺医药发展有限公司 盐酸伊立替康新晶型及其制备方法
US7572803B2 (en) * 2007-10-25 2009-08-11 The Christus Stehlin Foundation For Cancer Research Hydrated crystalline esters of camptothecin
IT1391757B1 (it) * 2008-11-11 2012-01-27 Antibioticos Spa Irinotecan cloridrato cristallino e metodi per la sua preparazione
US8546573B2 (en) 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
WO2012007952A1 (en) * 2010-07-12 2012-01-19 Hetero Research Foundation Novel polymorph of irinotecan hydrochloride
CN102311443B (zh) * 2011-08-24 2014-07-16 上海北卡医药技术有限公司 盐酸伊立替康的新晶型及其制备方法
CN102617584B (zh) * 2012-03-14 2013-10-16 海南锦瑞制药股份有限公司 一种盐酸伊立替康化合物及其药物组合物
CN102850363B (zh) * 2012-09-18 2013-07-10 山东罗欣药业股份有限公司 盐酸伊立替康化合物及其药物组合物
MY180365A (en) 2013-04-15 2020-11-28 Regeneron Pharma Markers of tumor cell response to anti-cancer therapy
CN105713004A (zh) * 2016-03-23 2016-06-29 杭州华东医药集团新药研究院有限公司 一种高品质盐酸伊立替康三水合物晶型的制备方法
US10919905B2 (en) * 2019-05-16 2021-02-16 Scinopharm Taiwan, Ltd. Polymorphism for irinotecan free base

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
AR015190A1 (es) * 1997-10-23 2001-04-18 Smithkline Beecham Corp Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
NZ534999A (en) 2002-03-01 2007-03-30 Pharmacia Italia Spa Crystalline polymorphic form c of irinotecan hydrochloride
CZ20022250A3 (cs) * 2002-06-27 2004-02-18 Pliva-Lachema A. S. Způsob výroby irinotekanu
CN100418970C (zh) 2003-02-25 2008-09-17 株式会社益力多本社 伊立替康盐酸盐的同质多晶的制造方法
WO2006016203A1 (en) * 2004-08-09 2006-02-16 Shilpa Medicare Limited An improved process for the preparation of irinotecan hydrochloride trihydrate
US20060046993A1 (en) * 2004-09-01 2006-03-02 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
ATE446299T1 (de) * 2005-02-07 2009-11-15 Fermion Oy Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
JP5133704B2 (ja) * 2005-02-08 2013-01-30 フェルミオン オサケ ユキチュア 製造方法

Also Published As

Publication number Publication date
WO2007035709A2 (en) 2007-03-29
CA2623117C (en) 2013-12-10
BRPI0616308A2 (pt) 2011-06-14
US7435818B2 (en) 2008-10-14
CN101277694A (zh) 2008-10-01
KR20080059244A (ko) 2008-06-26
EP1951235B1 (en) 2010-03-10
AU2006292328B2 (en) 2012-12-20
JP5119153B2 (ja) 2013-01-16
EP2082741A1 (en) 2009-07-29
EP1951235A4 (en) 2008-10-29
CN101277694B (zh) 2011-04-20
DE602006012871D1 (de) 2010-04-22
WO2007035709A3 (en) 2007-10-25
ES2343204T3 (es) 2010-07-26
US20070072890A1 (en) 2007-03-29
ATE460162T1 (de) 2010-03-15
KR101150504B1 (ko) 2012-07-09
AU2006292328A1 (en) 2007-03-29
CA2623117A1 (en) 2007-03-29
EP1951235A2 (en) 2008-08-06
JP2009508874A (ja) 2009-03-05
NZ566807A (en) 2011-05-27

Similar Documents

Publication Publication Date Title
AR129907A2 (es) FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(b-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO, COMPOSICIÓN FARMACÉUTICA, PROCESO PARA LA PREPARACIÓN Y USOS
AR063347A1 (es) Formas cristalinas de docetaxel y proceso para su preparacion
MY141194A (en) Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts
IL187359A (en) Tigzycline crystalline form i, a preparation containing it, a process for its preparation and use for the preparation of a pharmacological preparation for parenteral use
WO2007048066A3 (en) Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
IL193951A (en) A compound with central pyrrolidine units, an intermediate compound for the preparation of the mediated compound, a process for the production of the mediated compound, the use of a mediated compound for the manufacture of a drug, a pharmaceutical preparation, a method for the preparation of a pharmaceutical preparation, and a method for making conventional pharmaceutical salt of a non-salts compound.
WO2007047863A3 (en) Crystals of laquinimod sodium, and process for the manufacture thereof
BRPI0817154A2 (pt) "método de modificar uma célula de levedura para a produção de etanol, célula de levedura modificada, uso de uma célula de levedura modificada e método para a produção de etanol"
MY167395A (en) Method for producing glufosinate p free acid
AR062134A1 (es) Erlotinib cristalino
EG23719A (en) New process for the synthesis of (I S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane and addition salts thereof, and application in the synthesis of I V abradine and addition salts thereof witha pharmaceutically acceptable acid
PE20081157A1 (es) Forma cristalina de hemifumarato de alisquireno
GEP20115343B (en) New method for preparing functionalised benzocyclo-butenes and its application to the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid
JP2015535287A5 (enExample)
AR080275A1 (es) Formas solidas de un derivado de n-( fenilmetil) propanamida y procedimientos de preparacion
WO2008010238A3 (en) Antidiabetic azabicyclo [3. 1. 0] hexan compounds
CN103864760B (zh) 一种盐酸法舒地尔化合物
WO2009122303A3 (en) Novel mandelate salt of fesoterodine
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
WO2008034912A3 (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
AR081514A1 (es) El compuesto 4-[etil(dimetil)amonio]butanoato, el metodo para la preparacion del mismo y el uso en el tratamiento de la enfermedad cardiovascular
CN101979376B (zh) 甘氨酰胺盐酸盐的制备方法
AR119184A1 (es) Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
ATE528301T1 (de) Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
WO2009084039A3 (en) Process for producing 1-[2-(dimethylamino)-1-(4-phenol)ethyl]cyclohexanol

Legal Events

Date Code Title Description
FB Suspension of granting procedure